These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 25643432)
1. The REDUCED (a RandomisED stUdy Comparing standard systemic anticoagulation thErapy to low Dose intracoronary anticoagulation therapy for elective percutaneous coronary intervention) trial. A novel pharmacologic regime for elective percutaneous coronary intervention. Ari H; Kivaç E; Ari S; Emlek N; Cetinkaya S; Celiloğlu N; Sarigul OY; Aydin C; Akkaya M; Koca V; Bozat T; Gurdogan M Acta Cardiol; 2014 Dec; 69(6):619-27. PubMed ID: 25643432 [TBL] [Abstract][Full Text] [Related]
2. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial. Montalescot G; Gallo R; White HD; Cohen M; Steg PG; Aylward PE; Bode C; Chiariello M; King SB; Harrington RA; Desmet WJ; Macaya C; Steinhubl SR; JACC Cardiovasc Interv; 2009 Nov; 2(11):1083-91. PubMed ID: 19926048 [TBL] [Abstract][Full Text] [Related]
3. The CIAO (Coronary Interventions Antiplatelet-based Only) Study: a randomized study comparing standard anticoagulation regimen to absence of anticoagulation for elective percutaneous coronary intervention. Stabile E; Nammas W; Salemme L; Sorropago G; Cioppa A; Tesorio T; Ambrosini V; Campopiano E; Popusoi G; Biondi Zoccai G; Rubino P J Am Coll Cardiol; 2008 Oct; 52(16):1293-8. PubMed ID: 18929239 [TBL] [Abstract][Full Text] [Related]
4. Intravenous enoxaparin versus unfractionated heparin in unselected patients undergoing percutaneous coronary interventions: the Zurich enoxaparin versus unfractionated heparin in PCI study (ZEUS). Bertel O; Ramsay D; Wettstein T; Kurz DJ; Stettler I; Straumann E; Frielingsdorf J; Maurer D; Naegeli B EuroIntervention; 2010 Aug; 6(3):407-12. PubMed ID: 20884422 [TBL] [Abstract][Full Text] [Related]
5. Utility of post-procedural anticoagulation after primary PCI for STEMI: insights from a pooled analysis of the HORIZONS-AMI and EUROMAX trials. Ducrocq G; Steg PG; Van't Hof A; Zeymer U; Mehran R; Hamm CW; Bernstein D; Prats J; Deliargyris EN; Stone GW Eur Heart J Acute Cardiovasc Care; 2017 Oct; 6(7):659-665. PubMed ID: 27287251 [TBL] [Abstract][Full Text] [Related]
6. Bivalirudin in percutaneous coronary intervention for chronic total occlusion: A single-center pilot study. Li C; Xu R; Shen Y; Dai Y; Zhang F; Ma J; Ge L; Qian J; Ge J Catheter Cardiovasc Interv; 2018 Mar; 91(4):679-685. PubMed ID: 28766879 [TBL] [Abstract][Full Text] [Related]
7. The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial. White HD; Gallo R; Cohen M; Steg PG; Aylward PE; Bode C; Steinhubl S; Montalescot G Am Heart J; 2009 Jan; 157(1):125-31. PubMed ID: 19081408 [TBL] [Abstract][Full Text] [Related]
8. Low-Dose Unfractionated Heparin with Sequential Enoxaparin in Patients with Diabetes Mellitus and Complex Coronary Artery Disease during Elective Percutaneous Coronary Intervention. Huang J; Li N; Li Z; Hou XJ; Li ZZ Chin Med J (Engl); 2018 Apr; 131(7):764-769. PubMed ID: 29578118 [TBL] [Abstract][Full Text] [Related]
9. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. Gibson CM; Murphy SA; Montalescot G; Morrow DA; Ardissino D; Cohen M; Gulba DC; Kracoff OH; Lewis BS; Roguin N; Antman EM; Braunwald E; J Am Coll Cardiol; 2007 Jun; 49(23):2238-46. PubMed ID: 17560287 [TBL] [Abstract][Full Text] [Related]
10. Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux. Steg PG; Mehta S; Jolly S; Xavier D; Rupprecht HJ; Lopez-Sendon JL; Chrolavicius S; Rao SV; Granger CB; Pogue J; Laing S; Yusuf S Am Heart J; 2010 Dec; 160(6):1029-34, 1034.e1. PubMed ID: 21146654 [TBL] [Abstract][Full Text] [Related]
11. ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. Schulz S; Mehilli J; Neumann FJ; Schuster T; Massberg S; Valina C; Seyfarth M; Pache J; Laugwitz KL; Büttner HJ; Ndrepepa G; Schömig A; Kastrati A; Eur Heart J; 2010 Oct; 31(20):2482-91. PubMed ID: 20805113 [TBL] [Abstract][Full Text] [Related]
12. Comparison of Safety and Efficacy of Unfractionated Heparin Versus Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention. Rehmani A; Judkins C; Whelan A; Nguyen M; Schultz C Heart Lung Circ; 2017 Dec; 26(12):1277-1281. PubMed ID: 28377232 [TBL] [Abstract][Full Text] [Related]
13. Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab. Dubois CL; Belmans A; Granger CB; Armstrong PW; Wallentin L; Fioretti PM; López-Sendón JL; Verheugt FW; Meyer J; Van de Werf F; J Am Coll Cardiol; 2003 Oct; 42(7):1178-85. PubMed ID: 14522476 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of triple antiplatelet therapy with and without concomitant anticoagulation during elective percutaneous coronary intervention (the REMOVE trial). Valencia R; Price MJ; Sawhney N; Lee SS; Wong GB; Gollapudi RR; Banares M; Schatz RA; Teirstein PS Am J Cardiol; 2007 Oct; 100(7):1099-102. PubMed ID: 17884370 [TBL] [Abstract][Full Text] [Related]
15. Editor's Choice- Heparin pre-treatment in patients with ST-segment elevation myocardial infarction and the risk of intracoronary thrombus and total vessel occlusion. Insights from the TASTE trial. Karlsson S; Andell P; Mohammad MA; Koul S; Olivecrona GK; James SK; Fröbert O; Erlinge D Eur Heart J Acute Cardiovasc Care; 2019 Feb; 8(1):15-23. PubMed ID: 28862032 [TBL] [Abstract][Full Text] [Related]
16. Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: a combined analysis. Borentain M; Montalescot G; Bouzamondo A; Choussat R; Hulot JS; Lechat P Catheter Cardiovasc Interv; 2005 Jun; 65(2):212-21. PubMed ID: 15900551 [TBL] [Abstract][Full Text] [Related]